Designation of oripavine as a basic class of controlled substance. Final rule.
This is a final rule issued by the Drug Enforcement Administration (DEA) designating oripavine (3-O-demethylthebaine or 6,7,8,14-tetradehydro-4,5-alpha-epoxy-6-methoxy-17-methylmorphinan-3-ol) as a basic class in schedule II of the Controlled Substances Act (CSA). Although oripavine was not previously listed in schedule II of the CSA, it has been controlled in the United States as a derivative of thebaine and, as such, is controlled as a schedule II controlled substance which includes "Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate." Oripavine is a derivative of thebaine, a natural constituent of opium, hence oripavine has been and continues to be, by virtue of the definition of "narcotic drug", a schedule II controlled substance. International control of oripavine in schedule I of the 1961 Single Convention on Narcotic Drugs (1961 Convention) during the 50th session of the Commission on Narcotic Drugs (CND) in 2007 prompted the DEA to specifically designate oripavine as a basic class of controlled substance in schedule II of the CSA.
D004335:Drug and Narcotic Control / Q000331:legislation & jurisprudence*; D006801:Humans; D009020:Morphine / Q000032:analysis; D009294:Narcotics / Q000138:chemical synthesis; D009892:Opium / Q000031:analogs & derivatives; D013797:Thebaine / Q000031:analogs & derivatives* / Q000145:classification; D014481:United States
D009294:Narcotics; D013797:Thebaine; D009020:Morphine; D009892:Opium